Navigation Links
AUA counters mainstream recommendations with new best practice statement on PSA testing
Date:4/26/2009

LINTHICUM, MD, April 27, 2009The American Urological Association (AUA) today issued new clinical guidance which directly contrasts recent recommendations issued by other major groups about prostate cancer screening, asserting that the prostate-specific antigen (PSA) test should be offered to well-informed, men aged 40 years or older who have a life expectancy of at least 10 years. The PSA test, as well as how it is used to guide patient care (e.g., at what age men should begin regular testing, intervals at which the test should be repeated, at what point a biopsy is necessary) is highly controversial; however, the AUA believes that, when offered and interpreted appropriately the PSA test may provide essential information for the diagnosis, pre-treatment staging or risk assessment and post-treatment monitoring of prostate cancer.

The new Best Practice Statement updates the AUA's previous guidance, which was issued in 2000. Major changes to the AUA statement include new recommendations about who should be considered for PSA testing, as well as when a biopsy is indicated following an abnormal PSA reading. According to the AUA, early detection and risk assessment of prostate cancer should be offered to well-informed men 40 years of age or older who have a life expectancy of at least 10 years. The future risk of prostate cancer is closely related to a man's PSA score; a baseline PSA level above the median for age 40 is a strong predictor of prostate cancer. Such testing may not only allow for earlier detection of more curable cancers, but may also allow for more efficient, less frequent testing. Men who wish to be screened for prostate cancer should have both a PSA test and a digital rectal exam (DRE). The Statement also notes that other factors such as family history, age, overall health and ethnicity should be combined with the results of PSA testing and physical examination in order to better determine the risk of prostate cancer. The Statement recommends that the benefits and risks of screening of prostate cancer should be discussed including the risk of over-detection, detecting some cancers which may not need immediate treatment

"The single most important message of this statement is that prostate cancer testing is an individual decision that patients of any age should make in conjunction with their physicians and urologists. There is no single standard that applies to all men, nor should there be at this time," Dr. Carroll said. He also notes that the "panel carefully reviewed the most recently reported trials of PSA testing in both the United States and Europe before finalizing their guidelines. The strengths and limitations of these trials are reviewed in the guideline."

In regard to biopsy, a continuum of risk exists at all values, and major studies have demonstrated that there is no safe PSA value below which a man may be reassured that he does not have biopsy-detectable prostate cancer. Therefore, the AUA does not recommend a single PSA threshold at which a biopsy should be obtained. Rather, the decision to biopsy should take into account additional factors, including free and total PSA, PSA velocity and density, patient age, family history, race/ethnicity, previous biopsy history and co-morbidities. Additionally, the AUA statement emphasizes that not all prostate cancers require active treatment and that not all prostate cancers are life-threatening. The decision to proceed to active treatments is one that men should discuss in detail with their urologists to determine whether active treatment is necessary, or whether surveillance may be an option for their prostate cancer.

"Prostate cancer comes in many forms, some aggressive and some not," said Peter Carroll, MD, chair of the panel that developed the Statement. "But the bottom line about prostate cancer testing is that we cannot counsel patients about next steps for cancer that we do not know exist." He also notes that "the AUA is committed to the timely, expert and appropriate care for men either with or at risk of getting prostate cancer and is prepared to revise these guidelines continuously as new information becomes available."

Additionally, the Best Practice Statement clarifies a number of key points about the use of PSA in treatment selection and post-treatment follow up of prostate cancer patients:

  • Serum PSA predicts the response of prostate cancer to local therapy.
  • Routine use of a bone scan is not required for staging asymptomatic men with clinically localized prostate cancer when their PSA level is equal to or less than 20.0 ng/mL.
  • Computed tomography or magnetic resonance imaging scans may be considered for the staging of men with high-risk clinically localized prostate cancer when the PSA is greater than 20.0 ng/mL or when locally advanced or when the Gleason score is greater than or equal to 8.
  • Pelvic lymph node dissection for clinically localized prostate cancer may not be necessary if the PSA is less than 10.0 ng/mL and the Gleason score is less than or equal to 6.
  • Periodic PSA determinations should be offered to detect disease recurrence.
  • Serum PSA should decrease and remain at undetectable levels after radical prostatectomy.
  • Serum PSA should fall to a low level following radiation therapy, high intensity focused ultrasound and cryotherapy and should not rise on successive occasions.
  • PSA nadir (low point) after androgen suppression therapy predicts mortality.
  • Bone scans are indicated for the detection of metastases following initial treatment for localized disease, but the PSA level that should prompt a bone scan is uncertain. Additional important prognostic information can be obtained by evaluation of PSA kinetics (velocity).
  • The kinetics of PSA rise after local therapy for prostate cancer can help distinguish between local and distant recurrence.

The new AUA statement is based on panel review of all available professional literature, members' clinical experience and expert opinion. The new statement will be available online to the public at www.AUAnet.org on Monday, April 27, 2009 at 7 a.m. EDT.


'/>"/>

Contact: Wendy Isett
wisett@auanet.org
410-977-4770
American Urological Association
Source:Eurekalert

Related medicine news :

1. Draeger Counters What It Believes Are Unsubstantiated Allegations of Patent Infringement by Sperian
2. Inaugural Big Expedition for Cancer Research Encounters Mountain As Challenging As Finding a Cure for Cancer
3. RealSelf.com Denies Lifestyle Lifts Trademark Claims and Files Countersuit
4. Health and Fashion - Dow Corning Predicts the Top Trends Driving Consumers to the Beauty Counters
5. Alvarado Hospital Files Countersuit Against Blue Shield
6. Align Technology Targets Mainstream Orthodontics Market With Invisalign Teen(TM)
7. NARALS CHOICE: Is Anyone Surprised About Out-of-the-Mainstream NARALs Choice of Barack Obama for President?
8. Trust for Americas Health Supports Recommendations from Robert Wood Johnson Foundation Commission to Build a Healthier America
9. National Council on Disability Makes Recommendations to Create More Federal Job Opportunities for People With Disabilities
10. Coalition to Protect Senior Care Urges House Ways and Means Panel to Reject MedPAC Recommendations on SNF Medicare Funding
11. AHRQ Issues Recommendations for Safeguarding Children During Public Health Emergencies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2016)... ... May 26, 2016 , ... On May 23rd during the National ... Science® and international water advocate, was honored by Ashram, Inc. as the world’s foremost ... who knelt on the banks of the Nile to fill their red clay pots ...
(Date:5/26/2016)... ... May 26, 2016 , ... The introduction of our ... PROTECTION TO YOUR HEAD ™”. , “We are proud to introduce Meghan ... football front we have Brian Quick, wide receiver for Los Angeles who was a ...
(Date:5/26/2016)... ... 26, 2016 , ... Metcalf & Associates’ Maureen Metcalf ... experience in leading technology and human resources operations for health care, education, banking, ... be featured on Metcalf’s VoiceAmerica radio show , Innovative Leaders Driving Thriving ...
(Date:5/26/2016)... , ... May 26, 2016 , ... May 2016 – ... so central to popular cosmetic improvement efforts. Record numbers of clients now ask about ... prominent or pouty, says Kally Papantoniou, MD, of Advanced Dermatology P.C. , ...
(Date:5/26/2016)... ... May 26, 2016 , ... ... is happy to announce the launch of its brand equity product, Brandvantage. ... to reflect the dynamic landscape of modern consumer decision-making. The proprietary framework ...
Breaking Medicine News(10 mins):
(Date:5/24/2016)... New Zealand , May 24, 2016 ... and informatics solutions for the healthcare sector, has been named ... New Zealand Hi-Tech Awards 2016. Dr Bruce ... fantastic acknowledgement for our team.  It,s really good to be ... burden healthcare internationally. Our products are used in 35 countries ...
(Date:5/24/2016)... Los innovadores de COMBO[TM], ... introduce catéteres para la intervención de extremidades inferiores ... global especializada en el suministro de soluciones vasculares ... incluyendo productos para tratar la enfermedad arterial periférica. ... los dispositivos de primera entrada de la compañía ...
(Date:5/23/2016)... , May 23, 2016 ... Handling Equipment Market by Product (Wheelchair, Scooters, Medical ... (Bariatric Care, Critical Care, Wound), Accessories (Lifting, Transfer) ... to 2021", published by MarketsandMarkets, the patient handling ... Billion by 2021 at a CAGR of 10.5% ...
Breaking Medicine Technology: